Functional Genomics Approach To Extend Lifespan While Preventing Age-related Cognitive Decline
Funder
National Health and Medical Research Council
Funding Amount
$772,600.00
Summary
In our ageing population, preventing age-related neurological decline is one of the central medical challenges of the 21st century. Here we use human population data obtained from people who reached 90 years of age free of any disease, or patients who suffer from dementia, combined with functional genomics studies in animals to pinpoint new genes that can be targeted to extend lifespan while preserving neurological function in these extended years of life.
In Vivo Tau Imaging In Alzheimer’s Disease And Other Dementias
Funder
National Health and Medical Research Council
Funding Amount
$538,998.00
Summary
Alteration of the normal protein tau leads to its deposition inside the brain cells leading to their death. These deposits have been well characterized and they are associated with cognitive impairment. We propose to study tau deposits in vivo in humans using positron emission tomography (PET) and assess its association with cognition and other signs of neurodegeneration
Inflammation plays both protective and damaging roles in Alzheimer’s disease (AD), so to identify a long lasting and effective treatment, it is important that we better understand the underlying processes. Our studies implicate a cytokine called interleukin-18 (IL-18) as a factor that accelerates AD pathology. Here we propose to study the mechanisms by which this cytokine alters basic cell biological functions and how these changes affect AD pathogenesis.
Investigating Interleukin-37 As A Treatment And Biomarker For Alzheimer’s Disease
Funder
National Health and Medical Research Council
Funding Amount
$677,857.00
Summary
Alzheimer’s disease (AD) is the defining healthcare condition of our generation. Finding asymptomatic at risk individuals at preclinical stages will allow initiation of therapies that will either slow or, preferably, stop the progression of the disease. Herein, we will study a protein called interleukin-37 as an early biomarker and treatment for AD.
Interaction Of Amyloid-beta And Tau Pathology In Alzheimer's Disease
Funder
National Health and Medical Research Council
Funding Amount
$122,592.00
Summary
Currently, over 200,000 Australians are affected by Alzheimer's disease (AD) and related forms of dementia, causing a huge socio-economic damage. To overcome the lack of effective treatments, we need to understand the underlying causes and translate them into therapy. Using state-of-the-art cell culture and genetic mouse models, I will reveal fundamental processes in AD and related dementias, and develop tailored treatments to battle these devastating disorders.
The Missing Link: MGluR5 As A Therapeutic Target For Cognitive Decline In Dementia
Funder
National Health and Medical Research Council
Funding Amount
$563,622.00
Summary
Cognitive decline is a core feature of Alzheimer’s Disease (AD), yet there is no cure or treatment. Recent evidence suggests that a protein called mGluR5 could cause brain cells to lose function, leading to memory loss. This project will investigate whether disrupting mGluR5 function can improve cognition in mice with genetic AD. Memory will be assessed in mice using innovative touchscreen tests that closely mimic the tests used in humans.
Huntington’s disease (HD) is a devastating neurodegenerative disorder which shares several features with Alzheimer’s and Parkinson’s disease (i.e. dementia-like cognitive deficits). There is currently no cure for HD. Using a mouse model of HD and a combination of relevant drugs (i.e. N-Acetylcysteine and deferiprone) targeting two distinct levels of the cascade of events leading to HD, we will slow down the progression of the disease and correct dysfunctions within the brain.
Optimising Exercise Prescription For Brain Health In Older Adults At Risk Of Dementia
Funder
National Health and Medical Research Council
Funding Amount
$594,123.00
Summary
To reduce dementia burdens in the community, cost effective and targeted early regenerative strategies are critical. Engaging in frequent aerobic exercise is one strategy that can delay the onset and slow the progression of dementia. However, prescription is limited by an incomplete understanding of how exercise positively influences brain health. Here I will investigate the influence of current exercise levels, intensity and exercise environment on brain health in adults at risk of dementia.
IRAP inhibitors are currently being developed as a new class of drugs for treating dementia and other forms of memory deficits. However, there are still gaps in our knowledge about how these drugs act to improve memory. The experiments outlined in this proposal will provide important insights into the drug action in different mouse models of memory deficit.